Zoetis is a category-creating animal-health leader temporarily squeezed by U.S. companion pricing and sentiment—yet valued near cycle lows ahead of a potential 2027/28 pipeline re-acceleration.
Overview
Zoetis is the global leader in animal health (~20% share) with a diversified, vertically integrated model spanning R&D through commercialization across medicines, vaccines, diagnostics, and emerging genomics. The industry benefits from shorter development cycles, lower regulatory friction, and a predominantly private-pay dynamic versus human pharma. Zoetis generates ~65% of revenue from companion animals (the core growth engine driven by pet humanization) and ~35% from livestock (historically stabilizing, currently benefiting from protein demand and vaccine needs). The U.S. contributes ~53% of revenue and is the key premium market; international (~47%) offers expansion runway. Its portfolio is broad and defensible—especially in mAbs—supported by a unique direct-to-vet commercial model that embeds Zoetis in clinical workflows. However, the latest quarter highlighted a tougher U.S. companion environment (traffic, pricing, and mAb sentiment), making the next pipeline wave (renal/oncology) critical to re-accelerating growth.